Abstract Background: Tumor markers were used in malignant pleural effusion with negative cytology.
Introduction
Malignant pleural effusion is diagnosed by positive cytology for malignant cells but pleural fluid cytology is negative in 50% of cases so, determination of tumor markers either in serum or pleural fluid has been used in the diagnosis of pleural malignancy [1] (see Fig. 1 ).
Cyfra 21-1 is a fragment of cytokeratin (CK) 19 which is the principal structural element of the cytoskeleton and expressed in the pseudostratified epithelium lining the bronchial tree [2] , and been reported to be overexpressed in many lung cancer tissue specimens [3] due to accelerated CK19 degradation as a result of increased protease activity of caspase 3, a regulator of the apoptosis cascade , leading to release of fragments into the blood resulting in an increase of the cyfra 21-1 level in serum and other body fluids [4] .
CEA is an oncofetal protein, elevates in the serum of patients with colorectal, gastrointestinal, lung and breast carcinomas and also differentiates between benign and malignant pleural effusions [5] . It is synthesized by malignant cells as an adhesion molecule that is implicated in cell aggregation [6] .
Aim of the work
To assess the diagnostic value of serum and pleural levels of cyfra 21-1 and CEA in differentiation between benign and malignant pleural effusion.
Patients and methods
This study was done in the Chest department -Tanta university hospital and Tanta chest hospital during the period from July 2013 to December 2013 and carried out on 48 patients with pleural effusions divided into: Group I: included 28 patients with benign pleural effusion divided into 3 subgroups, (A): included eight patients (four males and four females) with parapneumonic pleural effusion, their mean age was 55.87 ± 11.420 years and characterized by the presence of acute fever with purulent sputum, pulmonary infiltrate, leukocytosis and neutrophilia with predominance of neutrophils in cellular analysis of pleural fluid [7] , (B): included ten patients (seven males and three Females) with tuberculous pleural effusion, their mean age was 35.70 ± 8.97 years and diagnosed by high positive tuberculin test, high ESR, lymphocytic pleural effusion, positive acid fast bacilli in sputum or pleural fluid and pleural fluid adenosine deaminase more than 40 u/l [8] and (C): included ten patients (seven males and three females) with transudative pleural effusion, their mean age was 56.60 ± 5.621 years and diagnosed according to Light's criteria by one of the following: -ratio of pleural fluid lactate dehydrogenase (LDH) to that in serum was less than 0.6, ratio of pleural fluid total protein to that in plasma was less than 0.5 and the LDH level in the pleural fluid needed to be less than two thirds of the serum level [7] . All of them were cardiac patients with congestive heart failure confirmed by echocardiography. Group II: included twenty patients (fifteen males and five females) with malignant pleural effusion, their mean age was 55.35 ± 8.13 years and diagnosed if pleural fluid cytology for malignant cells was positive [7] .
Exclusion criteria:
patients under chemo-therapy or radio-therapy, immuno-compromised patients, patients with bleeding tendency. 
Statistical analysis
Statistics of this study was conducted using mean, standard deviation, analysis of variance (ANOVA) test, sensitivity and specificity by SPSS V.20.
Results
There was a significant decrease of age (year) in the tuberculous group compared with other groups, and there were no significant differences between parapneumonic, transudative and malignant groups. There was a significant decrease of serum to pleural protein ratio in the transudative group compared to other groups and the malignant group was significantly decreased compared to the other two groups and there was a significant increase in parapneumonic patients compared to the tuberculous group. There was no significant difference of pleural to serum LDH ratio between all groups. Pleural total leukocytic count was significantly higher in the tuberculous group compared with other groups and it was significantly higher in the malignant group compared to both other groups but, there was a significant decrease in the transudative group compared to the parapneumonic group. Serum and pleural levels of cyfra 21-1and CEA were significantly increased in the malignant group compared to other groups but there were no significant differences between parapneumonic, tuberculous and transudative groups. Sensitivities of cyfra 21-1 and CEA in serum were 90.4 and 90.5 and in pleural fluid were 94.7 and 92.6 respectively, the specificities of cyfra 21-1 and CEA in serum were 86.9 and 83.5 respectively and in pleural fluid were 89.3 and 85.8 respectively but sensitivity of both cyfra 21-1 and CEA in serum and pleural fluid was 100, specificities in serum and pleural fluid were 92.86 and 96.43 respectively (see Fig. 2 and Tables 1-3) .
Discussion
In the present study the mean cyfra 21-1 and CEA levels in serum and pleural fluid were significantly higher in malignant ROC Curve Diagonal segments are produced by ties. [14] . Radjenovic-Petkovic et al., studied the diagnostic value of CEA in pleural fluid for differential diagnosis of benign and malignant pleural effusions .Their study was carried on eighty-two patients with pleural effusion, forty-one with malignant, and forty-one with non-malignant effusion and concluded that CEA may represent a helpful adjunct to cytology in order to include malignancy as a probable diagnosis, thus guiding the selection of patients for more invasive procedures [15] , Korczynski et al. found that the median pleural fluid concentrations of the investigated tumor markers (CEA, cyfra 21-1, and NSE) were significantly higher in malignant exudates compared with non-malignant effusions [16] . Hackbarth et al., concluded that measurement of CEA in pleural fluid was significantly higher in pleural fluids of malignant effusions compared to non-malignant effusions. In all cases, analysis of CEA was superior to CA19-9 in identifying effusions of malignant origin [17] . Huang et al., concluded that cyfra 21-1 is a useful tumor marker for discriminating malignant effusion due to lung adenocarcinoma from benign pleural effusion and CEA has both the greatest sensitivity and specificity for the diagnosis of patients with malignant pleural effusion [5] . Farag et al., concluded that cyfra 21-1 is a non-invasive reliable marker for differentiating malignant from benign pleural effusions either it is used as a single marker or in combination with CA15-3 so, negative cyfra 21-1 patients might not proceed to unnecessary thoracoscopy [7] . Azimi et al., concluded that cyfra 21-1 is helpful in diagnosing benign cases from malignant cases [18] and Hsieh et al. found that cyfra 21-1, and CEA were significantly higher in lung adenocarcinoma-cytology negative pleural effusion when compared with the benign one [19] (see Table 4 ). In the present study, a combination of cyfra 21-1 and CEA in serum and pleural fluid had higher sensitivity and accuracy Lee and Chang found that the combination of cyfra and CEA in serum and pleural fluid had a higher sensitivity and accuracy than each one alone [11] . Huang et al., found that cyfra 21-1 combined with CEA in pleural fluids increased diagnostic sensitivity to 66.7% in differentiation of lung adenocarcinoma-associated cytologically negative pleural effusions from benign ones when compared with either cyfra 21-1 or CEA [5] (see Tables 5 and 6 ).
In the present study, serum cyfra 21-1 and CEA had nearly the same sensitivity but cyfra 21-1 had a higher specificity and accuracy than CEA. Pleural fluid cyfra 21-1 had a higher sensitivity, specificity and accuracy than CEA. Wagner et al. found that serum cyfra 21-1 had a higher sensitivity than CEA in differentiation between benign and malignant pleural effusions [12] , also Korczynski et al., found that serum cyfra 21-1 had a higher sensitivity and accuracy than CEA [16] , but Shitrit et al. found that CEA had a higher sensitivity, specificity and accuracy than cyfra (21-1) because this study included patients with lung adenocarcinoma and CEA is known to be higher in these patients [10] . In the present study, there was a significant increase in cyfra 21-1 and CEA levels in pleural fluid compared with serum in malignant pleural effusions. Lee and Chang found that there was a significant increase in cyfra 21-1 levels in pleural fluids compared with serum in malignant pleural effusions, also there was a significant increase in CEA levels in pleural fluids compared with serum in malignant pleural effusions [11] . Wagner et al., and Biaoxue, found that, the cyfra 21-1 and CEA levels were significantly higher in the pleural fluid than in the serum in patients with malignant pleural effusion [12, 20] because of decreased lymphatic drainage caused by lymphatic obstruction due to pleural invasion [21] so this study concluded that measurement of cyfra 21-1 and CEA in serum and pleural fluid is helpful in differentiation between benign and malignant pleural effusions but pleural fluid cyfra 21-1 and CEA were more helpful than those of serum. Cyfra 21-1 is more accurate than CEA in differentiation between benign and malignant pleural effusions but a combination of cyfra 21-1 and CEA in serum and pleural 
